Jan 19, 2023 09:07 JST

Source: Eisai

Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company

TOKYO, Jan 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced that it has been listed in the 2023 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's seventh inclusion on the list. Ranked 53rd, Eisai was the highest ranking company among global pharmaceutical companies (please visit here(New Window) for the Global 100 ranking).

The Global 100 evaluates the sustainability of more than 6,000 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year. The Global 100 is based on up to 25 key performance indicators covering ESG initiatives, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai was highly evaluated, particularly in indicators for enhancing employee value such as safe work environment, sick leave support system and employee retention rate.

Eisai's corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. Based on this human health care (hhc) corporate concept, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Lecanemab Receives Priority Review Status in Japan
January 30 2023 11:50 JST
 
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
January 27 2023 10:46 JST
 
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
January 19 2023 09:35 JST
 
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
January 18 2023 12:28 JST
 
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
January 16 2023 17:56 JST
 
Eisai Launches Renewed Sustainability Page
January 13 2023 14:06 JST
 
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
January 11 2023 11:52 JST
 
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
January 09 2023 20:55 JST
 
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
January 09 2023 19:40 JST
 
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 22 2022 17:07 JST
 
More Press release >>

Latest Press Release


More Latest Release >>